Both radiation and temozolomide, a generic chemotherapy treatment in pill form, have meaningful single-modality anti-tumor activity against slow-growing, low-grade gliomas. The randomized phase 3 ...

A group led by the Department of Neurosurgery at the Brain Research Institute, Niigata University, has successfully treated a patient with a brainstem glioma harboring a rare IDH2 mutation. The case ...

After decades of limited progress—owing to the difficulty of treating the disease and resultant market risk—glioblastoma ...

The addition of temozolomide to radiation therapy prolonged OS for patients with both co-deleted and non-co-deleted grade 2 gliomas, according to study results.These are the first data from a ...

The addition of veliparib to adjuvant temozolomide failed to improve OS for patients with newly diagnosed, MGMT-hypermethylated glioblastoma, according to randomized phase 2/phase3 study results ...

Assessment of low-grade glioma treatment response remains as much of a challenge as the treatment itself. Proton magnetic resonance spectroscopy (1H-MRS) and imaging were incorporated into a study ...

May 23, 2007 — Data from a retrospective review of a large single-center experience confirm that treatment with temozolomide (TMZ; Temodar, Temodal, Schering-Plough) is effective against low ...

Is Single-Agent Temozolomide the Treatment of Choice for Recurrent Primary Central Nervous System Lymphoma? Antonio M.P. Omuro Disclosures Nat Clin Pract Oncol. 2007;4 (9):514-515. 0 ...

How to Take Temozolomide and it's Dose Written by - Dhanalakshmi Chinnuswamy, Diploma in Pharmacy, MBA (Healthcare) Medically Checked by - Dr. M. Sree Mohana Preetha, Doctor of Pharmacy ...

This study investigated the treatment of primary CNS lymphoma with methotrexate, temozolomide (TMZ), and rituximab, followed by hyperfractionated whole-brain radiotherapy (hWBRT) and subsequent TMZ.

Temozolomide has an acceptable tolerance in elderly patients with GBM and KPS less than 70. It is associated with improvement of functional status in 33% of patients and appears to increase survival ...